Aberrant signaling through the RAS/RAF/MEK/ERK pathway is a characteristic feature of many cancers, including LGSOC, with, 5%-16% and 16%-47% of LGSOCs having alterations in BRAF and RAS, respectively.3-7. This evidence concerns the gene MAP2K7 and cancer.